Dr Alan Burguete-Torres (Mexico) reviews recent data on immunotherapy in gastroesophageal cancer.


Introduction

Hello, I’m Dr Alan Burguete and I would like to welcome you to this GI CONNECT video newsletter.

I am really happy to share with you today some of the major advances that we saw in 2020 regarding the role of immunotherapy in upper GI cancer.

CheckMate-649

The first message I would like to share with you, is that we now have a new standard of care in the first-line, advanced setting for gastric cancer. The CheckMate-649 trial demonstrated a 3-month overall survival benefit in patients with PD-L1 CPS score ≥5 with a combination of nivolumab plus standard, platinum-based, chemotherapy. One of the caveats of this trial is that this was a PD-L1 enriched population, with over 60% of patients having a CPS score ≥5 and might not reflect what we see in the general population.

KEYNOTE-590

The second, practice changing trial for patients with advanced oesophageal cancer is the KEYNOTE-590 study which also demonstrated a benefit in progression-free and overall survival, particularly in patients with squamous oesophageal and PD-L1 expression with a CPS score ≥10.

CheckMate-577

The last trial I would like to share with you is CheckMate-577, which also demonstrated a substantial benefit in progression-free survival with the addition of nivolumab in the adjuvant setting for patients with oesophageal cancer who were treated with neoadjuvant chemoradiotherapy and surgery.

Conclusion

So these are, in my opinion, the three most important advances regarding the role of immunotherapy in upper GI cancers.

I hope this information was useful for you and I hope to see you soon. Thanks for watching.

Dr Alan Burguete-Torres M.D. is a dedicated gastrointestinal oncologist and Associate Professor of Medicine at the University of Nuevo Leon in Monterrey, Mexico. He earned his medical degree and completed a 4-year Internal Medicine fellowship at Tecnológico de Monterrey and later completed a 3-year fellowship in Medical Oncology at the University of Nuevo Leon. He later attended University of Valencia – INCLIVA Biomedical Research Institute for a short-term fellowship in gastrointestinal oncology under the mentorship of Prof. Andrés Cervantes in Valencia, Spain. He is currently Head of the Gastrointestinal Tumors Unit at the University of Nuevo León Cancer Center and actively participates and coordinates GI oncology MDT meetings at both private and public institutions. Currently, Dr Burguete-Torres has his private practice in gastrointestinal oncology at ONCARE Cancer Center and Centro Médico Zambrano Hellion – Tecnológico de Monterrey. He is also member of the European Society of Digestive Oncology (ESDO), European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and Mexican Society of Oncology (SMEO). His main research interest is in colorectal and gastroesophageal cancers.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved

Other programmes of interest

publication Publication
Oncology 
LEAP-012 publication

Expert insights on multimodal treatment for intermediate HCC

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery
ELPA
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
video Video
Oncology Hemato-oncology 
Innovating relapsed refractory multiple myeloma care

Unmet needs, therapy management, and real-world experience

Experts
Assoc. Prof. María Victoria Mateos, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Elena Zamagni
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
interactive-patient-case Interactive patient case
Oncology 
NTRK fusion testing and treatment in paediatric sarcoma

Make decisions for a young patient during his cancer journey

Experts
Dr Theodore Laetsch
Endorsed by
NTRKers
  • clock 15 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
micro-learning Micro learning

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
DiCE ELPA Global Liver Institute
Blue Faery AASLD
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
interactive-patient-case Interactive patient case
Oncology 
Later-line treatment strategies in metastatic colorectal cancer (mCRC)

Rechallenge vs switching

Experts
Prof. Andrea Sartore-Bianchi
Endorsed by
DiCE ICAN international cancer advocacy network
  • clock 15 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Highlights from ASCO 2025

Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Prof. Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED